Literature DB >> 8194366

Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields.

U Pleyer1, B Elkins, D Rückert, S Lutz, J Grammer, J Chou, K H Schmidt, B J Mondino.   

Abstract

We investigated the ability of liposomes to deliver the immunosuppressive agent cyclosporine A (CsA) to the cornea, anterior sclera, aqueous humor, and vitreous in rabbit eyes. One drop (10 microliters) of liposome-encapsulated CsA (CsA-LIP) or olive oil drops containing an equivalent concentration of CsA (CsA-DR) were administered at 15-minute intervals within the first hour and then one hourly over a 6-hour period. In addition, collagen shields soaked for 30 minutes in the liposome preparation (CsA-LIP-CS) were tested in vitro and in vivo as a new drug delivery approach. CsA levels were measured by fluorescence-immunoassay after 1, 3, or 6 hours of drug administration. CsA levels in this study were highest in cornea and anterior sclera. In animals receiving either CsA-DR or CsA-LIP, CsA levels generally increased from 1 to 6 hours. In animals receiving a single application of CsA-CS-LIP, CsA levels peaked at 3 hours and declined at 6 hours in cornea and sclera. CsA-LIP and CsA-CS-LIP delivered significantly higher levels of CsA to the cornea and sclera at 1 and 3 hours than CsA-DR. In aqueous and vitreous humor, CsA levels increased from 1 to 6 hours in animals receiving either CsA-DR or CsA-LIP. On the other hand, animals receiving a single application of CsA-CS-LIP had lower levels of CsA at 6 hours than at the earlier time points. Animals receiving CsA-LIP or CsA-CS-LIP had significantly higher levels of CsA in aqueous and vitreous humor at 1, 3, and 6 hours than animals receiving CsA-DR.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194366     DOI: 10.3109/02713689408995775

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  9 in total

1.  Cyclosporine A formulation affects its ocular distribution in rabbits.

Authors:  Mitsuaki Kuwano; Hajime Ibuki; Nobuo Morikawa; Atsutoshi Ota; Yoichi Kawashima
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

Review 2.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

3.  Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A.

Authors:  P Calvo; A Sanchez; J Martinez; M I Lopez; M Calonge; J C Pastor; M J Alonso
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 4.  Systemic cyclosporine and corneal transplantation.

Authors:  Mohammed Ziaei; Fatemeh Ziaei; Bita Manzouri
Journal:  Int Ophthalmol       Date:  2016-02       Impact factor: 2.031

5.  Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.

Authors:  Kishore Cholkar; Ashaben Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Recent Pat Nanomed       Date:  2012

Review 6.  Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.

Authors:  I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

7.  Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture.

Authors:  P Cortina; M J Gómez-Lechón; A Navea; J L Menezo; M C Terencio; M Diaz-Llopis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-03       Impact factor: 3.117

Review 8.  An overview on dry eye treatment: approaches for cyclosporin a delivery.

Authors:  Burçin Yavuz; Sibel Bozdağ Pehlivan; Nurşen Unlü
Journal:  ScientificWorldJournal       Date:  2012-04-24

Review 9.  Ocular Drug, Gene and Cellular Delivery Systems and Advanced Therapy Medicinal Products.

Authors:  Türkan Eldem; Bora Eldem
Journal:  Turk J Ophthalmol       Date:  2018-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.